文献速递肿瘤 PET/CT

边缘区淋巴瘤患者FDG-PET/CT亲和性的临床与病理预测因素:一项回顾性队列研究

Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-26

该单中心回顾性队列研究纳入2006年1月至2020年12月在Rabin医学中心诊断的207例边缘区淋巴瘤成人患者,评估诊断时FDG-PET/CT的亲和性预测因素。36.7%患者为FDG亲和,多因素分析显示非胃MALT、Ki 67≥15%和LDH升高与FDG亲和阳性相关,并建立SUVmax预测模型。

要点

  • 207例边缘区淋巴瘤患者中36.7%为FDG亲和。
  • 非胃MALT、Ki 67≥15%和LDH升高与FDG亲和阳性独立相关。
  • 基线FDG亲和仅在单因素分析中与无进展生存和总生存相关。

核心结论

  • 该回顾性队列研究提出了边缘区淋巴瘤患者FDG摄取阳性和SUVmax的预测模型,旨在帮助临床医生选择适合纳入FDG-PET/CT进行分期和监测疾病的患者,并减少冗余检查的费用。

研究设计与样本

  • 单中心回顾性队列研究,纳入2006年1月至2020年12月在Rabin医学中心诊断的207例边缘区淋巴瘤成人患者,均于诊断时接受FDG-PET/CT。

主要发现

  • 207例患者中76例(36.7%)为FDG亲和。
  • 多因素logistic回归模型中,非胃MALT(OR 4.2,95%CI 1.78-10)、Ki 67指数≥15%(OR 3.64,95%CI 1.36-9.76)和LDH水平升高(OR 8.6,95%CI 3.2-22.8)均与FDG亲和阳性相关。
  • 多因素线性回归模型中,晚期临床分期、特定疾病亚型、LDH水平和Ki 67指数的组合预测SUVmax(P值<0.001;校正R2=33.8%)和SUVmax/SUVliver(P值<0.001;校正R2=27%)。
  • 基线FDG亲和仅在单因素分析中与无进展生存和总生存相关。

关键数值与推荐

  • FDG亲和定义为视觉评估至少为中等强度。
  • 非胃MALT的OR为4.2(95%CI 1.78-10),Ki 67≥15%的OR为3.64(95%CI 1.36-9.76),LDH升高的OR为8.6(95%CI 3.2-22.8)。
  • SUVmax预测模型的P值<0.001,校正R2=33.8%;SUVmax/SUVliver预测模型的P值<0.001,校正R2=27%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical value of FDG-PET/CT for staging and monitoring treatment response in patients with aggressive lymphoma is well established. Conversely, its role in the assessment and management of marginal zone lymphoma (MZL) is less conclusive. We aimed to assess clinical, laboratory, and pathological predictors for FDG uptake in these patients, in an attempt to identify MZL patients whose management will benefit from this imaging modality. METHODS: In this single-center, retrospective cohort study, we included all adult patients diagnosed with MZL at the Rabin Medical Center between January 2006 and December 2020 who underwent FDG-PET/CT at the time of diagnosis. Primary outcomes were FDG avidity (defined as a visual assessment of at least moderate intensity), SUVmax, and SUVliver. Variables such as advanced clinical stage, primary disease site, hemoglobin level (Hb), platelet count (Plt), serum albumin, LDH level, β-2 microglobulin, and Ki 67 index were evaluated univariate and multivariate analysis using logistic and linear regression models. Association between FDG avidity and progression-free and overall survival was evaluated using Kaplan-Meier curves and Cox regression analysis. RESULTS: A total of 207 MZL patients were included in this study, 76 of whom (36.7%) had FDG-avid disease. Baseline patients' characteristics such as age, gender, and comorbid conditions were similar between patients with and without significant FDG uptake. In a multivariate logistic regression model, non-gastric MALT (OR 4.2, 95% CI 1.78-10), Ki 67 index ≥ 15% (OR 3.64, 95% CI 1.36-9.76), and elevated LDH level (OR 8.6, 95% CI 3.2-22.8) were all associated with positive FDG avidity. In a multivariate linear regression model, a combination of advanced clinical stage, specific disease subtypes, LDH level, and Ki 67 index predicted the value of SUVmax (P value < 0.001; adjusted R2 = 33.8%) and SUVmax/SUVliver (P value < 0.001; adjusted R2 = 27%). Baseline FDG avidity was associated to PFS and OS only in univariate analyses. CONCLUSIONS: In this retrospective cohort study, we present prediction models for positive FDG uptake and SUVmax in MZL patients. These models aim to help clinicians choose patients suitable for incorporation of FDG-PET/CT for staging and monitoring disease and reduce the costs of redundant tests.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kagan KBT, Guz D, Buchrits S, et al. Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study. Eur J Nucl Med Mol Imaging. 2022. PMID: 35079846. doi:10.1007/s00259-022-05683-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。